Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis

類似資料

• Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
  著者:: Bruin, Gerard, 等
  出版事項: (2019)
• Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
  著者:: Timmermann, Stine, 等
  出版事項: (2019)
• Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
  著者:: Pariser, David, 等
  出版事項: (2017)
• Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
  著者:: Kircik, Leon, 等
  出版事項: (2016)
• Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
  著者:: Menter, Alan, 等
  出版事項: (2016)